A Phase 1 interventional study of ONO-2808 and Placebo in Neurodegenerative Diseases, sponsored by Ono Pharmaceutical Co. Ltd. Completed at 1 site in United Kingdom. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-12-30.
Sponsored by Ono Pharmaceutical Co. Ltd · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 50 studies in Neurodegenerative Diseases with a site in United Kingdom — 11 open to participants now, 19 under way, 4 of them phase 3. Neurodegenerative Diseases · United Kingdom.
Among the 50 studies in Neurodegenerative Diseases with a site in United Kingdom, this one is the 21st largest by enrollment of the 40 interventional ones that give a count, is one of 3 that started in 2020, is one of 7 in phase 1, and was the 21st registered.
436 studies on the registry are indexed under Neurodegenerative Diseases; 143 are open to participants now.
Browse Neurodegenerative Diseases studies →11 of the 50 studies in Neurodegenerative Diseases with a site in United Kingdom are open now. Recruiting first, the newest first:
Nutricia UK Ltd · Sites in United Kingdom
Ages 3+
University College, London · Sites in United Kingdom
Ages 35–75
Alnylam Pharmaceuticals · Sites in United Kingdom, Canada, Germany
Ages 25–70
Eli Lilly and Company · Sites in United Kingdom, United States, Japan
Ages 50–85
Friedreich's Ataxia Research Alliance · Sites in United Kingdom, United States, Australia and 14 more countries
Healthy volunteers
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 101 Neurodegenerative Diseases studies recruiting now, 52 (51%) set no upper age limit and 11 (11%) stop at 75 or younger; 20 take children under 18; 49 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
50 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 14 · Phase 3 16
First in 2008; this study’s year is marked. 3 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 94 is above the median of 54 across 265 interventional studies indexed under Neurodegenerative Diseases.
Median enrollment 119 across the 40 interventional studies, 44 across the 9 observational. Of the 27 that completed or were terminated, 10 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
38 of 50 have an industry lead sponsor. The 10 most frequent:
Ono Pharmaceutical Co. Ltd is the lead sponsor of 63 studies on the registry; 2 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 1 (20%) have results posted.
Ono Pharmaceutical Co. Ltd has 1 study filed under Neurodegenerative Diseases — fewer than ten, so there is no comparison to draw.
3 of the studies in Neurodegenerative Diseases with a site in United Kingdom that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06268886Bristol-Myers SquibbStudy to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease | 2026-12-17 |
| NCT06877923Nutricia UK LtdElemental 028 Extra Case Studies | 2027-02 |
| NCT06185764Vertex Pharmaceuticals IncorporatedA Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1) | 2027-02-02 |
Add all 3 to your calendar (.ics) → With an account.
Among the 50 studies in Neurodegenerative Diseases with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a first in human study to determine the safety, tolerability and pharmacokinetics of ONO-2808 in healthy adult participants. The study will be conducted in 3 parts: Part A, a single-ascending dose part with an assessment of the potential food effects in non-Japanese adult participants; Part B, a single dose part to assess the effect of age in non-Japanese elderly participants; and Part C, a multiple-ascending dose part with ONO-2808 administered to healthy subjects.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants who are not willing to eat a high fat breakfast
Exclusion criteria, applicable to all participants undergoing lumbar puncture for CSF collection (Part A \& C):
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single ascending doses of ONO-2808 or placebo orally under fasted conditions. Additional descriptive information (including which interventions are administered in each arm) to differentiate each arm from other arms in the clinical trial.
Drug: ONO-2808
Single ascending doses of ONO-2808 or placebo orally under fasted conditions
Drug: Placebo
Single ascending doses of ONO-2808 or placebo orally under fed conditions
Drug: ONO-2808
Single ascending doses of ONO-2808 or placebo orally under fed conditions
Drug: Placebo
Single dose of ONO-2808 or placebo in elderly female or elderly male healthy volunteers .
Drug: ONO-2808
Single dose of ONO-2808 or placebo in elderly female or elderly male healthy volunteers
Drug: Placebo
Multiple ascending doses of ONO-2808 or placebo orally
Drug: ONO-2808
Multiple ascending doses of ONO-2808 or placebo orally
Drug: Placebo
Investigational drug
Placebo drug
Treatment emergent adverse events (TEAEs) by severity.
Number of participants with TEAEs. An adverse event is any untoward medical occurrence in a participant who receive study drug without regard to possible causal relationship.
Time frame: Part A and B: up to day 7; Part C: up to 17 days.
Serious adverse events (SAEs)
Number of participants with SAEs. An SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death, initial or prolonged hospitalization, life-threatening experience or persistent disability.
Time frame: Part A and B: up to day 7; Part C: up to 17 days.
Vital signs
Summary statistics of vital signs and number of participants with clinically significant changes in vital signs including pulse/heart rate, respiratory rate, and blood pressure
Time frame: Part A and B: up to day 7; Part C: up to 17 days
ECG parameters
Number of participants with ECG abnormalities
Time frame: Part A and B: up to day 7; Part C: up to 17 days.
Clinical laboratory tests
Number of participants with clinical laboratory abnormalities (including haematology, clinical chemistry and urinalysis)
Time frame: Part A and B: up to day 7; Part C: up to 17 days
Physical examination
Number of participants with physical examination abnormalities
Time frame: Part A and B: up to day 7; Part C: up to 17 days
Neurological examination
Number of participants with neurological examination abnormalities
Time frame: Part A and B: up to day 7; Part C: up to 17 days.
Number of participants with suicidal behaviour
Treatment-emergent suicidal ideation and behaviour will be monitored by using the Columbia Suicide Severity Rating Scale (C-SSRS) and reported.
Time frame: Part C: up to 17 days
Pharmacokinetics (Cmax)
Assessment of the maximum observed plasma concentration of ONO-2808
Time frame: Part A & B: Day 1 through Day 7, Part C: Day 1 and 14
Pharmacokinetics (Tmax)
Assessment of the time to reach Tmax for ONO-2808
Time frame: Part A & B: Day 1 through Day 7, Part C: Day 1 and 14
Pharmacokinetics (AUClast)
Assessment of the area under the concentration-time curve of ONO-2808 to last measurable concentration
Time frame: Part A & B: Day 1 through Day 7
Pharmacokinetics (AUCinf)
Assessment of the area under the concentration-time curve of ONO-2808 extrapolated to infinite time in plasma
Time frame: Part A & B: Day 1 through Day 7
Pharmacokinetics (AUCtau)
Assessment of the area under the concentration-time curve of ONO-2808 during the dosing interval in plasma
Time frame: Part C: Day 1 and Day 14
Pharmacokinetics (T1/2)
Assessment of the terminal elimination half-time of ONO-2808 in plasma
Time frame: Part A & B: Day 1 through Day 7
Pharmacokinetics (CL/F)
Assessment of the apparent clearance of ONO-2808 from plasma
Time frame: Part A & B: Day 1 through Day 7
Pharmacokinetics (Vz/F)
Assessment of the apparent volume of distribution of ONO-2808 during terminal elimination phase
Time frame: Part A & B: Day 1 through Day 7
Pharmacokinetics (Aetz)
Assessment of the amount of ONO-2808 excreted in urine over the period of sample collection
Time frame: Part A & B: Day 1 through Day 5, Part C: Day 1, 8 & 14
Pharmacokinetics (Percentage fe)
Assessment of the cumulative percentage of orally administered ONO-2808 excreted into urine
Time frame: Part A & B: Day 1 through Day 5, Part C: Day 1, 8 & 14
Pharmacokinetics (CLR)
Assessment of the renal clearance of ONO-2808 from plasma
Time frame: Part A & B: Day 1 through Day 5, Part C: Day 1, 8 & 14.
Distribution of ONO-2808 to the brain in Part A
Assessment of ONO-2808 brain distribution by measuring drug concentration in the cerebro spinal fluid (CSF)
Time frame: Part A (in selected fasted cohorts): Day 1 and 2, Part C: Day 1 and Day 14
Plan to share: No
No publications or documents are linked to this record.
Ran from Aug 2020 to primary completion in Aug 2021, 12 months.
Of 29 phase 1 interventional studies under Neurodegenerative Diseases, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 41. This study's 12 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: ONO-2808